Technologies

Pharmaceuticals & Vitamin D : Neurological & mental health

Pharmaceuticals & Vitamin D Portfolios

Technologies

Retinoic Acid: A New Treatment for Sleep Apnea and Hypopnea

UW–Madison researchers have developed a new method for treating sleep apnea and hypopnea with retinoic acid.

A patient can be given a retinoid or retinoic acid receptor agonist such as all-trans RA (ATRA), 13-cis RA (isotretinoin) or 9-cis RA (alitretinoin). These compounds target the mechanisms that cause sleep apnea in two ways. First, they increase the respiratory drive (urge to breathe). Additionally, they reduce the apneic threshold (the level of CO2 necessary for the induction of breath) to normal levels.
P150330US02

Treatment of Fragile X Syndrome Using Nutlin-3

UW–Madison researchers have discovered that Nutlin-3, a candidate antitumor drug, and its derivatives may be useful for treating patients with FXS or other intellectual disability. This is the first time that Nutlin-3 has been shown to inhibit adult neural stem cell proliferation and rescue cognitive deficits in a FXS mouse model.

Nutlin-3 is a small molecule MDM2-p53 pathway inhibitor developed in 2004. The researchers use <10x dosage for FXS compared to the dosage used for cancer treatment.
P150380US02

Peptides to Treat Alzheimer’s Disease

UW–Madison researchers have developed a new strategy to design peptides that could be turned into therapeutics to treat or halt the progression of Alzheimer’s disease. The cyclized (ring-shaped) peptides are derived from transthyretin (TTR), a protein found in cerebrospinal fluid that is known to bind to Aβ and inhibit its toxicity in vitro and in vivo. The new peptides mimic both the sequence and the hairpin structure of transthyretin’s Aβ binding domain.
P140391US02

Treating Absence Epilepsy with Ganaxolone

UW–Madison researchers have developed a method for treating absence epilepsy with the drug ganaxolone, a synthetic neurosteroid analog that modulates GABAA receptors. The drug has shown promise for treating other forms of epilepsy but has not been recommended for absence epilepsy until now.

The researchers have found that in low doses the drug provides an optimal amount of tonic inhibition that restores function and reduces symptoms in a mouse model. The drug may be particularly useful for treating young patients whose condition is characterized by a reduction in tonic inhibition.
P140051US02

Enzyme Aids Intranasal Drug Delivery

UW–Madison researchers have developed a method to enhance intranasal drug absorption using a naturally occurring endopeptidase, called matrix metalloproteinase-9 (MMP-9). This enzyme makes the nasal epithelium more permeable to drugs by degrading type IV collagen. Nasal spray or drops containing MMP-9 can be administered at the same time or prior to a drug to improve its absorption.
P120322US02

New Treatment for Restenosis

UW–Madison researchers have developed an anti-restenosis formula made of insulin and connective tissue growth factor (CTGF). CTGF is a large protein known to help grow and remodel smooth vessel muscle after damage. The combination of CTGF and insulin increases levels of elastic collagen (type III) to promote healthy healing. The composition can be applied as an external wrap at the site of surgery.
P120330US02

Treating Multiple Sclerosis with UV Light

UW–Madison researchers have developed a method for suppressing MS symptoms by irradiating a patient with a narrow band of ultraviolet (UV) light. The light has a wavelength between about 300-315 nm. Patients could be irradiated using commercially available lamps or blankets. A typical treatment regimen could be 10-30 minutes of exposure for several days.
P120376US02

BACE1 Inhibitors Reduce β-Amyloid Production, Provide Potential Treatment for Alzheimer’s Disease

The UW–Madison researcher now has identified two compounds that can downregulate BACE1 levels and the rate of β-amyloid production and thus may be potential therapeutics for Alzheimer’s disease. These compounds inhibit the activity of ATase1 and ATase2.
P100028US02

Benzodiazepine Derivatives with Reduced Side Effects for Treatment of Neuropathic Pain

Researchers at the University of Wisconsin-Milwaukee have developed new benzodiazepine derivatives useful in the treatment of neuropathic pain with reduced sedative and ataxic effects. GABA is the major inhibitory neurotransmitter in the central nervous system. Non-selective benzodiazepine drugs, such as valium, act by enhancing the inhibitory effects of GABA at GABAA receptors in the CNS. These drugs broadly target GABAA receptors containing a1, a2, a3, or a5 subunits.

Recently, it was discovered that the various effects of non-selective benzodiazepines are specifically mediated through certain a subunit-containing GABAA receptor populations in the brain. a1-containing GABAA receptors control sedation, whereas the anti-anxiety and anti-pain activity works mainly through a2 and a3 receptors. a5 receptors play critical roles in learning and memory consolidation.

The inventors of this technology have produced GABAA receptor agonists specific for a2 and a3 receptors. Because the compounds do not affect a1 receptors, they have significant neuropathic pain protection without sedative and ataxic effects. In addition, the compounds are anxiolytic and anti-convulsant. The inventors are carrying out pre-clinical testing of these compounds by conducting in vitro studies and animal studies in rats, mice and monkeys. These compounds were found to have significant neuropathic pain protection in mice and rats without causing sedation, muscle relaxation or ataxic effect.
T09021US02

Borane-Protected Phosphine Molecules Save Cells from Death and Damage

UW–Madison researchers have developed a method for protecting cells from neurodegenerative injury, radiation damage and other causes of cell death.  The method involves exposing neuronal, endothelial or other mammalian cells to one or more of several borane-protected phosphine molecules created by the researchers.  These protective molecules have good cell permeability and chemical stability and are useful for treating or preventing cell-death related diseases and conditions in human and non-human animals.
P09152US02

Sigma 1 Receptor Inhibitors May Provide New Cancer, Psychosis, Addiction and Other Therapies

UW-Madison researchers have discovered a new class of compounds that are high affinity inhibitors of the sigma 1 receptor. These compounds are cytotoxic against many cancer cell lines, including breast, lung, prostate, ovarian, colorectal and CNS. They could be used as antipsychotic agents, to treat cocaine addiction or cardiovascular disorders or to inhibit the growth of cancer cells.

The inventors characterized the sigma 1 receptor ligand binding regions to define novel and essential features of the molecular scaffold of high affinity ligands. They found that long chain alkylamines are a key feature of ligands, such as the fungicide tridemorph, that bind to the sigma 1 receptor with high affinity and inhibit its activity.
P09097US02

Treating Alexander Disease by Reducing Expression of Glial Fibrilary Acidic Protein (GFAP)

UW-Madison researchers have developed methods of treating Alexander disease by down-regulating the expression of GFAP. They identified several compounds, including known antidepressants, antipsychotics, serotonin inhibitors and antihistamines, which are capable of reducing GFAP expression.

When administered to a patient with Alexander disease, the compounds should lessen the symptoms of the disease. They may reduce the intensity of the megalencephaly, or abnormally large brain, associated with Alexander disease; the amount of Rosenthal fibers, which are widely deposited in astrocytes in patients with the disease; and/or the intensity or frequency of seizures.
P09011US02

Novel Subtype of Botulinum Toxin For Pharmaceutical Use

UW–Madison researchers have isolated a novel plasmid found in a C. botulinum type A strain that is not neutralized by antibodies. The plasmid encodes genes for subtypes BoNT/A3 or BoNT/A4 and BoNT/B. The neurotoxins can be purified and formulated into pharmaceuticals or vaccines.
P06269US

Method of Reducing Neural Cell Death

UW-Madison researchers have developed a method of reducing neuronal cell death. Neuronal cells are exposed to a boron-protected phenylphosphine, such as bis(3-propionic acid methyl ester)phenylphosphine borane complex or (3-propionic acid methyl ester)diphenylphosphine borane complex. These compounds, successfully tested in rats, are highly neuroprotective at nanomolar and picomolar concentrations, respectively.
P04304US

Anti-Anxiety Pharmaceuticals with Reduced Side Effects

A team of researchers at UW-Milwaukee have developed novel benzodiazepine derivatives that offer increased binding sensitivity at GABA type A receptors while decreasing the negative side effects associated with these therapeutics. These orally-active derivatives, and salts thereof, provide enhanced anxiolytic activity with little or no sedative, hypnotic or muscle relaxing effects. These compounds were found to reduce situational anxiety in rats without causing significant sedation, muscle relaxation or ataxic effects. These benzodiazepine derivatives offer hope for more effective treatment of anxiety disorders in the future.
T02017US

Method of Targeting Pharmaceuticals to Motor Neurons

UW-Madison researchers have developed a method for delivering therapeutic drugs to motor neurons. This method could be used to treat botulism, which is caused by botulinum neurotoxin, a potentially serious biological warfare agent. It involves synthesizing a therapeutic molecule covalently bound to a polymeric delivery vehicle and conjugating it to a botulinum neurotoxin heavy chain. The botulinum neurotoxin heavy chain acts as a vehicle for delivery of pharmaceuticals to motor neurons.
P00282US

Long-Lasting Chimeric Botulinal Toxins

UW–Madison researchers have developed a chimeric toxin comprising a botulinal neurotoxin heavy chain and nonclostridial toxin chain. The chimeric toxin has a longer lasting effect, reducing side effects and frequency of treatment.
P97017US